New broad patent strengthens Allergy Therapeutics portfolio

Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process.

The AIM-traded firm said the patent covers the novel manufacture and physiochemical characteristics of MCT in combination with one or more antigens, further strengthening the its core intellectual property.

It added that the granting of the patent also strengthens its wholly-owned subsidiary Bencard Adjuvant Systems, which specialises in developing and optimising aluminium-free adjuvants for infectious diseases.

Recent data has shown how MCT has a synergistic effect when coupled with another adjuvant from BAS's portfolio, ‘virus-like particles’, to create the adjuvant system AdSys-VcT, it said.

As the company announced recently, the adjuvant system demonstrated protective efficacy in a malaria model in a study performed in collaboration with the University of Oxford.

“We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines, both in allergies and also in infectious disease areas such as malaria and influenza,” said CEO Manuel Llobet.

“This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines.”